LGND Ligand Pharmaceuticals
Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenx Inc., the company went public in 1992.
Company profile
Ticker
LGND, LGNXZ, LGNYZ, LGNZZ, LGNDZ
Exchange
Website
CEO
John Higgins
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LIGAND PHARMACEUTICALS
SEC CIK
Corporate docs
IRS number
770160744
LGND stock data
()
News
Roth Capital Maintains Buy on Ligand Pharmaceuticals, Lowers Price Target to $190
30 Jul 21
Ligand Sees FY21 Adj. EPS $5.80-$6.05 vs $6.12 Est., Sales $265M-$275M vs $280.44M Est.
29 Jul 21
Ligand Pharmaceuticals Q2 Adj. EPS $1.63 Beats $1.34 Estimate, Sales $84.70M Beat $70.41M Estimate
29 Jul 21
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
29 Jul 21
Earnings Scheduled For July 29, 2021
29 Jul 21
Press releases
Ligand Reports Second Quarter 2021 Financial Results
29 Jul 21
Landing AI's LandingLens™ visual inspection software platform selected by Ligand Pharmaceuticals to further empower the OmniAb® and xPloration™ antibody discovery platforms
28 Jul 21
Ligand's Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
19 Jul 21
Ligand to Report Second Quarter Financial Results on July 29, 2021
16 Jul 21
Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors
14 Jul 21
Investment data
Securities sold
Number of investors
Calendar
6 May 21
31 Jul 21
31 Dec 21
Financial summary
Quarter (USD) |
Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Financial data from company earnings reports.
| Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 32.2M | 32.2M | 32.2M | 32.2M | 32.2M | 32.2M |
| Cash burn (monthly) | 5.26M | 7.17M | (positive/no burn) | (positive/no burn) | (positive/no burn) | (positive/no burn) |
| Cash used (since last report) | 21.11M | 28.81M | n/a | n/a | n/a | n/a |
| Cash remaining | 11.08M | 3.38M | n/a | n/a | n/a | n/a |
| Runway (months of cash) | 2.1 | 0.5 | n/a | n/a | n/a | n/a |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 12 Jul 21 | Jennifer R. Cochran | Common Stock | Grant | Aquire A | No | No | 0 | 1,161 | 0 | 1,161 |
| 12 Jul 21 | Jennifer R. Cochran | NQSO Common Stock | Grant | Aquire A | No | No | 126.36 | 4,508 | 569.63K | 4,508 |
| 30 Jun 21 | Higgins John L | Common Stock | Other | Aquire J | No | No | 85.9095 | 247 | 21.22K | 338,095 |
| 30 Jun 21 | Korenberg Matthew E | Common Stock | Other | Aquire J | No | No | 85.9095 | 247 | 21.22K | 39,690 |
| 4 Jun 21 | Patel Sunil | Common Stock | Grant | Aquire A | No | No | 0 | 630 | 0 | 28,820 |
| 4 Jun 21 | Patel Sunil | NQSO Common Stock | Grant | Aquire A | No | No | 115.39 | 3,269 | 377.21K | 3,269 |
Institutional ownership Q1 2021
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
91.5% owned by funds/institutions
13F holders |
Current |
|---|---|
| Total holders | 221 |
| Opened positions | 37 |
| Closed positions | 51 |
| Increased positions | 56 |
| Reduced positions | 101 |
13F shares |
Current |
|---|---|
| Total value | 2.32B |
| Total shares | 15.24M |
| Total puts | 596.6K |
| Total calls | 294.9K |
| Total put/call ratio | 2.0 |
Largest owners |
Shares | Value |
|---|---|---|
| BLK Blackrock | 2.13M | $324.17M |
| Vanguard | 1.52M | $231.46M |
| William Blair Investment Management | 1.29M | $196.85M |
| JHG Janus Henderson | 1.26M | $191.75M |
| STT State Street | 782.76K | $119.33M |
| Villere ST Denis J & Co | 537.03K | $81.87M |
| Conestoga Capital Advisors | 495.88K | $75.6M |
| MCQEF Macquarie | 484.36K | $73.84M |
| Chicago Capital | 448.64K | $68.4M |
| Rice Hall James & Associates | 430.06K | $65.56M |
Financial report summary
?Management Discussion
- Royalty revenue is a function of our partners’ product sales and the applicable royalty rate. Kyprolis royalty rates are under a tiered royalty rate structure with the highest tier being 3.0%. Evomela has a fixed royalty rate of 20%. Contract revenue includes service revenue, license fees and development, regulatory and sales based milestone payments.
- Royalty revenue increased slightly in Q1 2021 compared to Q1 2020. Captisol sales increased in Q1 2021 compared to Q1 2020, primarily reflecting higher sales of Captisol for use in the manufacturing of remdesivir. Contract revenue increased in Q1 2021 compared to Q1 2020, with the increase primarily attributable to 1) the timing of partner milestone events and 2) the additional contract revenue of $4.2 million and $3.3 million from the acquisitions of Icagen in April 2020 and Pfenex in October 2020, respectively.
- Total operating costs and expenses increased by $21.1 million, or 72%, primarily due to the acquisition of Pfenex on October 1, 2020 and Icagen on April 1, 2020, as well as increase in Captisol sales revenue for the current period.
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
AACR, Abvivo, accelerated, acceleration, adult, affirmative, AI, aldehyde, Aldeyra, allegedly, allergic, alliance, Appeal, appointed, Aptevo, Arcellx, BI, biosimilar, bispecific, breach, breached, Breakthrough, Brian, BTD, carfilzomib, clearance, cohort, consent, construction, construing, consummated, covalent, CPLSA, create, Darzalex, denied, denying, dexamethasone, dismissed, disputed, dosage, downstream, duty, ELAINE, endometrial, engineered, ENKTL, EU, evolution, examine, experienced, expert, extranodal, false, fiduciary, Forsteo, fraudulently, Gertz, GlaxoSmithKline, GSK, hematological, Huntsman, induced, Intelligence, interventional, invasive, INVIGORATE, isatuximab, itching, Jay, joint, lab, lack, landscape, lawsuit, linked, Livogiva, loyalty, Lundstrom, mAb, maximum, medicine, monoclonal, motion, NASDAQ, negotiate, ocular, older, OMT, ophthalmic, oppose, Orphan, PDUFA, Pelican, percentile, powered, prejudice, priority, professor, PTAB, ranked, RASP, reactive, Recombinant, reconciliation, relapsed, relationship, reproxalap, respondent, Sarclisa, score, secondary, shareholder, simulation, slightly, solution, stayed, stop, tearing, temporary, teriparatide, thereof, Thermarex, Toxin, track, Travere, unique, University, unmet, unvested, unwind, urged, User, Utah, violation, withdraw, withheld, workforce
Removed:
accept, administration, altogether, amendment, analyze, area, avoid, base, began, borrowing, Branch, California, candidate, care, characterized, charge, Clarifying, collaborator, commencement, comparing, complexity, conduct, confidence, congentia, consistent, contact, counterparty, dependent, depreciable, design, desire, determinable, developed, discovered, disruption, distancing, diversion, document, duration, epidemic, equipment, evolve, excluding, expended, expensed, extend, facility, forced, foreseeable, Francisco, funding, furlough, genetically, globe, good, healthcare, heightening, hospital, hypothetical, identify, Immunovant, implicit, important, imposed, inception, insurance, integrity, Interaction, invention, laboratory, leasehold, located, location, London, maintenance, measuring, monitoring, nonclinical, obligated, OmniRat, oncology, opening, outsourced, pachyonychia, past, people, Pharma, pivotal, preclude, presenting, produce, production, Promacta, promote, prospective, quantifying, receiving, recent, recommended, recruiting, refusal, rent, representing, requirement, residual, restated, restrictive, Retrophin, retrospective, Roivant, San, serving, Simplifying, site, social, South, staffing, Subsequent, supportable, termination, test, tested, title, Topic, transition, transport, travel, variable, Verona, worked
Financial reports
10-Q
2021 Q1
Quarterly report
6 May 21
10-K
2020 FY
Annual report
23 Feb 21
10-Q
2020 Q3
Quarterly report
6 Nov 20
10-Q
2020 Q2
Quarterly report
7 Aug 20
10-Q
2020 Q1
Quarterly report
8 May 20
10-K
2019 FY
Annual report
27 Feb 20
10-Q
2019 Q3
Quarterly report
8 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K
2018 FY
Annual report
28 Feb 19
Current reports
8-K
Ligand Reports Second Quarter 2021 Financial Results
29 Jul 21
8-K
Other Events
21 Jul 21
8-K
Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors
14 Jul 21
8-K
Submission of Matters to a Vote of Security Holders
6 Jun 21
8-K
Ligand Reports First Quarter 2021 Financial Results
3 May 21
8-K
Ligand Reports Fourth Quarter and Full Year 2020 Financial Results
3 Feb 21
8-K
Entry into a Material Definitive Agreement
28 Jan 21
8-K
Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
21 Dec 20
8-K
Departure of Directors or Certain Officers
16 Dec 20
8-K/A
Financial Statements and Exhibits
10 Dec 20
Registration and prospectus
S-8
Registration of securities for employees
27 Jan 21
SC TO-T/A
Third party tender offer statement (amended)
30 Sep 20
SC TO-T/A
Third party tender offer statement (amended)
16 Sep 20
SC TO-T/A
Third party tender offer statement (amended)
11 Sep 20
SC TO-T
Third party tender offer statement
31 Aug 20
SC TO-C
Information about tender offer
10 Aug 20
SC TO-C
Information about tender offer
10 Aug 20
S-8
Registration of securities for employees
8 Aug 19
S-8
Registration of securities for employees
28 Jul 16
D
$85.44M in equity, sold $85.44M, 22 investors
24 Jan 16
Proxies
DEFA14A
Additional proxy soliciting materials
18 May 21
DEFA14A
Additional proxy soliciting materials
23 Apr 21
DEF 14A
Definitive proxy
23 Apr 21
DEF 14A
Definitive proxy
12 Nov 20
PRE 14A
Preliminary proxy
30 Oct 20
DEFA14A
Additional proxy soliciting materials
24 Apr 20
DEF 14A
Definitive proxy
24 Apr 20
DEFA14A
Additional proxy soliciting materials
4 Jun 19
DEF 14A
Definitive proxy
23 Apr 19
DEFA14A
Additional proxy soliciting materials
23 Apr 19
Other
UPLOAD
Letter from SEC
12 Jan 21
CORRESP
Correspondence with SEC
5 Jan 21
UPLOAD
Letter from SEC
22 Dec 20
CORRESP
Correspondence with SEC
15 Sep 20
CT ORDER
Confidential treatment order
15 Jun 20
CT ORDER
Confidential treatment order
23 Aug 18
CT ORDER
Confidential treatment order
22 May 18
CT ORDER
Confidential treatment order
2 Apr 18
UPLOAD
Letter from SEC
6 Feb 18
CORRESP
Correspondence with SEC
16 Jan 18
Ownership
4
LIGAND PHARMACEUTICALS / Jennifer R. Cochran ownership change
14 Jul 21
3
LIGAND PHARMACEUTICALS / Jennifer R. Cochran ownership change
14 Jul 21
4
LIGAND PHARMACEUTICALS / JOHN L HIGGINS ownership change
2 Jul 21
4
LIGAND PHARMACEUTICALS / Matthew E Korenberg ownership change
2 Jul 21
4
LIGAND PHARMACEUTICALS / Stephen L Sabba ownership change
8 Jun 21
4
LIGAND PHARMACEUTICALS / Jason Aryeh ownership change
7 Jun 21
4
LIGAND PHARMACEUTICALS / Sarah Boyce ownership change
7 Jun 21
4
LIGAND PHARMACEUTICALS / Todd C Davis ownership change
7 Jun 21
4
LIGAND PHARMACEUTICALS / Nancy Ryan Gray ownership change
7 Jun 21
4
LIGAND PHARMACEUTICALS / JOHN W KOZARICH ownership change
7 Jun 21
Patents
APP
Utility
a Monoclonal Antibody Against Human 4-1BB, Method for Preparing the Same, and Use Thereof
29 Jul 21
Provided are novel fully human monoclonal antibodies that bind to human 4-1BB.
APP
Utility
Glucagon Receptor Antagonists
29 Apr 21
Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity.
GRANT
Utility
Method for analysis using X-ray fluorescence
16 Mar 21
The present invention is a method to quantify biomarkers.
APP
Utility
Methods and Compositions Associated with the Granulocyte Colony-stimulating Factor Receptor
18 Feb 21
Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR).
APP
Utility
Imidazo-fused Heterocycles and Uses Thereof
11 Feb 21
Compounds and methods in the fields of chemistry and medicine are disclosed.
Transcripts
2021 Q2
Earnings call transcript
30 Jul 21
2021 Q1
Earnings call transcript
4 May 21
2020 Q4
Earnings call transcript
3 Feb 21
2020 Q3
Earnings call transcript
30 Oct 20
2020 Q2
Earnings call transcript
3 Aug 20
2020 Q1
Earnings call transcript
6 May 20
2019 Q3
Earnings call transcript
5 Nov 19
2019 Q2
Earnings call transcript
30 Jul 19
2019 Q1
Earnings call transcript
2 May 19
2018 Q4
Earnings call transcript
8 Feb 19
Reddit threads
Daily Discussion Thread - July 29th, 2021
29 Jul 21
Daily Discussion Thread - July 28th, 2021
28 Jul 21
Daily Discussion Thread - July 27th, 2021
27 Jul 21
Daily Discussion Thread - July 26th, 2021
26 Jul 21
which is your small-cap tech stock?
9 May 21
Daily Discussion Thread - May 3rd, 2021
3 May 21
Daily Discussion Thread - April 30th, 2021
30 Apr 21
Buying The Dip
18 Apr 21
Daily Discussion Thread for March 02, 2021
2 Mar 21
Don’t feel so bad. This loss wiped out my GME gains completely. Holding.
21 Feb 21